Literature DB >> 9357528

Potent anandamide analogs: the effect of changing the length and branching of the end pentyl chain.

W J Ryan1, W K Banner, J L Wiley, B R Martin, R K Razdan.   

Abstract

To examine the effect of changing the length and branching of the end pentyl chain (C5H11) of anandamide (AN), various analogs 1a-h and 2a-f were synthesized from either the known aldehyde ester 6a or from the alcohol 6b and tested for their pharmacological activity. A reproducible procedure was developed for the conversion of arachidonic acid to 6a or 6b in gram quantities (overall yield 15%). The appropriate tetraene esters 7 were prepared by carrying out a Witting reaction, between 6a and the ylide generated from the phosphonium salt of the appropriate alkyl halide or between the ylide of 6d (prepared from 6a-->6b-->6c-->6d) and the appropriate alkyl aldehydes. They were then hydrolyzed to the corresponding acids and transformed into AN analogs 1 via their acid chlorides then treated with excess ethanolamine. alpha-Alkylation of esters 7 gave compounds 8 which were hydrolyzed to the corresponding acids. These acids via their acid chlorides and subsequent treatment with excess fluoroethylamine gave the target compounds 2. In this way analogs 1e and 2a-c were synthesized from 6d while all the remaining analogs were prepared from 6a. In order to assess the optimal length of the alkyl terminus, analogs 1a-d were prepared and showed moderately high affinities (18-55 nM). However analogs 1a-c failed to produce significant pharmacological effects at doses up to 30 mg/kg. Analog 1d was found to be a weak partial agonist. The reason for the lack of activity in 1a-c is presently not clear. Like the THCs, the branching of the end pentyl chain in AN (1e-h) increased potency both in in vitro and in vivo activities; the dimethylheptyl (DMH) analog 1e was the most potent in the series. Similar alkyl substitutions were carried out in the fluoro-2-methylanandamide series (2a-f), and all of these analogs had high receptor affinities (1-14 nM), the DMH analog 2a being the most potent. With a few exceptions they showed robust pharmacological effects, and AN-like profiles. It was shown that the SAR of the end pentyl chain in AN is very similar to that of THCs. However, the magnitude of enhanced potency observed when the side chain of THC was changed from straight to branched was not observed when the end chain of AN was similarly changed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9357528     DOI: 10.1021/jm970212f

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

1.  Dissimilar cannabinoid substitution patterns in mice trained to discriminate Δ(9)-tetrahydrocannabinol or methanandamide from vehicle.

Authors:  Jenny L Wiley; D Matthew Walentiny; Robert E Vann; Cassandra Y Baskfield
Journal:  Behav Pharmacol       Date:  2011-09       Impact factor: 2.293

2.  Asymmetric synthesis of novel N-(1-phenyl-2,3-dihydroxypropyl)arachidonylamides and evaluation of their anti-inflammatory activity.

Authors:  Padmanabha V Kattamuri; Rebecca Salmonsen; Catherine McQuain; Sumner Burstein; Hao Sun; Guigen Li
Journal:  Life Sci       Date:  2012-07-20       Impact factor: 5.037

3.  Microsomal omega-hydroxylated metabolites of N-arachidonoyl dopamine are active at recombinant human TRPV1 receptors.

Authors:  N Rimmerman; H B Bradshaw; A Basnet; B Tan; Theodore S Widlanski; J M Walker
Journal:  Prostaglandins Other Lipid Mediat       Date:  2008-09-02       Impact factor: 3.072

4.  Novel, potent THC/anandamide (hybrid) analogs.

Authors:  Caryl Bourne; Sucharita Roy; Jenny L Wiley; Billy R Martin; Brian F Thomas; Anu Mahadevan; Raj K Razdan
Journal:  Bioorg Med Chem       Date:  2007-08-25       Impact factor: 3.641

5.  Unique agonist-bound cannabinoid CB1 receptor conformations indicate agonist specificity in signaling.

Authors:  Teodora Georgieva; Savitha Devanathan; Dagmar Stropova; Chad K Park; Zdzislaw Salamon; Gordon Tollin; Victor J Hruby; William R Roeske; Henry I Yamamura; Eva Varga
Journal:  Eur J Pharmacol       Date:  2007-11-28       Impact factor: 4.432

6.  Vascular pharmacology of a novel cannabinoid-like compound, 3-(5-dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1-methyl-ethyl)benzamide (VSN16) in the rat.

Authors:  P M Hoi; C Visintin; M Okuyama; S M Gardiner; S S Kaup; T Bennett; D Baker; D L Selwood; C R Hiley
Journal:  Br J Pharmacol       Date:  2007-09-24       Impact factor: 8.739

7.  Development of novel tail-modified anandamide analogs.

Authors:  Fenmei Yao; Chen Li; Subramanian K Vadivel; Anna L Bowman; Alexandros Makriyannis
Journal:  Bioorg Med Chem Lett       Date:  2008-07-31       Impact factor: 2.823

8.  Neuropharmacology of the endocannabinoid signaling system-molecular mechanisms, biological actions and synaptic plasticity.

Authors:  Balapal S Basavarajappa
Journal:  Curr Neuropharmacol       Date:  2007       Impact factor: 7.363

Review 9.  Endocannabinoid binding to the cannabinoid receptors: what is known and what remains unknown.

Authors:  Patricia H Reggio
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.